Next Article in Journal
Acknowledgement to Reviewers of the Journal of Clinical Medicine in 2014
Next Article in Special Issue
Design of a Tumorigenicity Test for Induced Pluripotent Stem Cell (iPSC)-Derived Cell Products
Previous Article in Journal
Hyponatremia in Patients with Cirrhosis of the Liver
Previous Article in Special Issue
The Potential for iPS-Derived Stem Cells as a Therapeutic Strategy for Spinal Cord Injury: Opportunities and Challenges
Article Menu

Export Article

Open AccessArticle
J. Clin. Med. 2015, 4(1), 102-123; doi:10.3390/jcm4010102

Scalable Electrophysiological Investigation of iPS Cell-Derived Cardiomyocytes Obtained by a Lentiviral Purification Strategy

1
Institute of Physiology I, Life and Brain Center, University of Bonn, Bonn 53127, Germany
2
Physical Chemistry I, University of Siegen, Siegen 57076, Germany
These authors contributed equally to this work.
*
Author to whom correspondence should be addressed.
Academic Editor: Michael J. Edel
Received: 20 August 2014 / Accepted: 9 December 2014 / Published: 8 January 2015
(This article belongs to the Special Issue iPS Cells for Modelling and Treatment of Human Diseases)
View Full-Text   |   Download PDF [608 KB, uploaded 20 January 2015]   |  

Abstract

Disease-specific induced pluripotent stem (iPS) cells can be generated from patients and differentiated into functional cardiomyocytes for characterization of the disease and for drug screening. In order to obtain pure cardiomyocytes for automated electrophysiological investigation, we here report a novel non-clonal purification strategy by using lentiviral gene transfer of a puromycin resistance gene under the control of a cardiac-specific promoter. We have applied this method to our previous reported wild-type and long QT syndrome 3 (LQTS 3)-specific mouse iPS cells and obtained a pure cardiomyocyte population. These cells were investigated by action potential analysis with manual and automatic planar patch clamp technologies, as well as by recording extracellular field potentials using a microelectrode array system. Action potentials and field potentials showed the characteristic prolongation at low heart rates in LQTS 3-specific, but not in wild-type iPS cell-derived cardiomyocytes. Hence, LQTS 3-specific cardiomyocytes can be purified from iPS cells with a lentiviral strategy, maintain the hallmarks of the LQTS 3 disease and can be used for automated electrophysiological characterization and drug screening. View Full-Text
Keywords: induced pluripotent stem cells; cardiomyocytes; purification; long QT syndrome; planar patch clamp; microelectrode array induced pluripotent stem cells; cardiomyocytes; purification; long QT syndrome; planar patch clamp; microelectrode array
Figures

Figure 1a

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Friedrichs, S.; Malan, D.; Voss, Y.; Sasse, P. Scalable Electrophysiological Investigation of iPS Cell-Derived Cardiomyocytes Obtained by a Lentiviral Purification Strategy. J. Clin. Med. 2015, 4, 102-123.

Show more citation formats Show less citations formats

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
J. Clin. Med. EISSN 2077-0383 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top